Alnylam Pharmaceuticals

Alnylam Pharmaceuticals ALNY Stock

$149.81   0.274434%
Add to favorites
Market Cap
$20.07B
LOW - HIGH [24H]
$146.51 - $152.70
VOLUME [24H]
$837.07K
P/E Ratio
7.56
Earnings per share
$19.80
ISIN
US02043Q1076
Price   Prediction

Alnylam Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Alnylam Pharmaceuticals (ALNY) stock price today is 149.81 USD on Tech Market Large (+0.27% on the day). Updated .

Alnylam Pharmaceuticals ALNY Financial and Trading Overview

Alnylam Pharmaceuticals stock price 149.81 USD
Previous Close 159.73 USD
Open 159.02 USD
Bid 161.11 USD x 100
Ask 156.58 USD x 200
Day's Range 155.79 - 160.64 USD
52 Week Range 149.18 - 479.79 USD
Volume 2.05M USD
Avg. Volume 2.06M USD
Market Cap 20.96B USD
Beta (5Y Monthly) 0.441
PE Ratio (TTM) 7.904041
EPS (TTM) 19.8 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 289.22 USD

ALNY Valuation Measures

Enterprise Value 20.37B USD
Trailing P/E 7.904041
Forward P/E 15.815878
PEG Ratio (5 yr expected) 0.22
Price/Sales (ttm) 4.181173
Price/Book (mrq) 5.8135214
Enterprise Value/Revenue 4.063
Enterprise Value/EBITDA 19.72

Trading Information

Alnylam Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.441
52-Week Change -65.44%
S&P500 52-Week Change 12.07%
52 Week High 479.79 USD
52 Week Low 149.18 USD
50-Day Moving Average 217.12 USD
200-Day Moving Average 274.59 USD

ALNY Share Statistics

Avg. Volume (3 month) 2.06M USD
Avg. Daily Volume (10-Days) 3.2M USD
Shares Outstanding 133.94M
Float 133.62M
Short Ratio 2.61
% Held by Insiders 0.20%
% Held by Institutions 105.61%
Shares Short 5.47M
Short % of Float 5.43%
Short % of Shares Outstanding 4.07%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 52.84%
Operating Margin (ttm) 19.50%
Gross Margin 77.27%
EBITDA Margin 20.60%

Management Effectiveness

Return on Assets (ttm) 9.51%
Return on Equity (ttm) 138.06%

Income Statement

Revenue (ttm) 5.01B USD
Revenue Per Share (ttm) 37.65 USD
Quarterly Revenue Growth (yoy) 16.69%
Gross Profit (ttm) 3.87B USD
EBITDA 1.03B USD
Net Income Avi to Common (ttm) 2.65B USD
Diluted EPS (ttm) 19.8
Quarterly Earnings Growth (yoy) 640.50%

Balance Sheet

Total Cash (mrq) 3.59B USD
Total Cash Per Share (mrq) 26.78 USD
Total Debt (mrq) 3B USD
Total Debt/Equity (mrq) 83.16 USD
Current Ratio (mrq) 2.478
Book Value Per Share (mrq) 26.92

Cash Flow Statement

Operating Cash Flow (ttm) 955.94M USD
Levered Free Cash Flow (ttm) 327.23M USD

Profile of Alnylam Pharmaceuticals

Country United States
State MA
City Cambridge
Address 675 West Kendall Street
ZIP 02142
Phone 617 551 8200
Website https://www.alnylam.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2500

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Q&A For Alnylam Pharmaceuticals Stock

What is a current ALNY stock price?

Alnylam Pharmaceuticals ALNY stock price today per share is 149.81 USD.

How to purchase Alnylam Pharmaceuticals stock?

You can buy ALNY shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Alnylam Pharmaceuticals?

The stock symbol or ticker of Alnylam Pharmaceuticals is ALNY.

Which industry does the Alnylam Pharmaceuticals company belong to?

The Alnylam Pharmaceuticals industry is Biotechnology.

How many shares does Alnylam Pharmaceuticals have in circulation?

The max supply of Alnylam Pharmaceuticals shares is 133.94M.

What is Alnylam Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Alnylam Pharmaceuticals PE Ratio is 7.56616160 now.

What was Alnylam Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Alnylam Pharmaceuticals EPS is 19.8 USD over the trailing 12 months.

Which sector does the Alnylam Pharmaceuticals company belong to?

The Alnylam Pharmaceuticals sector is Healthcare.

Alnylam Pharmaceuticals ALNY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3888.92 USD —
-0.27
51.92M USD — 3856.79 USD — 3919.64 USD — — 51.92M USD —
us US Tech Q-50 NXTQ US 1179.02 USD —
-0.05
— — 1168.83 USD — 1196.31 USD — — — —
us US Tech Global Select Market Com NQGS US 11949.46 USD —
-0.71
— — 11825.17 USD — 12288.24 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 29950.1 USD —
-0.8
— — 29671.6 USD — 30826.03 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2246.21 USD —
-1.59
— — 2233.15 USD — 2284.66 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3605.34 USD —
-0.97
— — 3577.02 USD — 3690.74 USD — — — —
us US Tech Next Generation 100 Inde NGX US 1686.49 USD —
-0.59
— — 1673.01 USD — 1717.15 USD — — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7603.91 USD —
-0.19
— — 7546.09 USD — 7685.86 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency